Cargando…
Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival
INTRODUCTION: Metastatic breast cancer (MBC) with leptomeningeal metastases (LM) has dismal survival. We aim to determine if modern systemic therapy, especially the bevacizumab, cisplatin, and etoposide (BEEP) regimen, is beneficial to MBC LM patients. METHODS: We excerpted data from a prospectively...
Autores principales: | Chen, Tom Wei-Wu, Jan, I-Shiow, Chang, Dwang-Ying, Lin, Ching-Hung, Chen, I-Chun, Chen, Ho-Min, Cheng, Ann-Lii, Lu, Yen-Shen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280357/ https://www.ncbi.nlm.nih.gov/pubmed/32346837 http://dx.doi.org/10.1007/s11060-020-03510-y |
Ejemplares similares
-
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
por: Wu, Pei-Fang, et al.
Publicado: (2015) -
Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020) -
Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023) -
Modelling suicide ideation from beep to beep: Application of network analysis to ecological momentary assessment data
por: Rath, Dajana, et al.
Publicado: (2019) -
Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia
por: Aminimoghaddam, Soheila, et al.
Publicado: (2018)